GC녹십자랩셀, Psoriasis Stem Cell Therapy Candidate Substance Clinical Phase 1 Application

[Asia Economy Reporter Eunmo Koo] GC Green Cross LabCell announced on the 21st that it has applied to the Ministry of Food and Drug Safety for a Phase 1 clinical trial administering the stem cell therapy candidate CT303 to patients with plaque psoriasis.

GC Green Cross LabCell plans to divide 24 patients with moderate to severe plaque psoriasis into two groups of 12 each, administering CT303 either once or multiple times to evaluate the drug's safety and tolerability. The clinical trial institutions are three domestic hospitals: Seoul National University Hospital, Pusan National University Hospital, and CHA University Bundang CHA Hospital.

CT303 is an allogeneic tonsil-derived mesenchymal stem cell product manufactured using tonsil tissue collected from healthy donors under the age of 10. GC Green Cross LabCell expects CT303 to help improve psoriasis symptoms by regulating excessive immune responses.

Psoriasis is a chronic skin disease in which skin keratinocytes grow too quickly, causing the stratum corneum to become abnormally thickened. Although the exact cause has not yet been identified, it is known as a type of autoimmune disease in which the immune system mistakenly attacks the skin as if it were an external substance.

This content was produced with the assistance of AI translation services.